---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-001975"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2023-02-16T23:59:59+00:00"
generated_at: "2026-06-19T09:17:54.217050+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alkermes FY2022 revenue $1.11B, GAAP loss per share $0.97; guides FY2023 revenue $1.13-1.25B

## Summary
- Q4 2022 total revenues $304.7M, GAAP net loss $0.17/share, non-GAAP diluted EPS $0.14.
- FY2022 proprietary net sales: VIVITROL $379.5M (+10%), ARISTADA $302.1M (+10%), LYBALVI $96.0M (first full year).
- FY2023 guidance: revenue $1.13-$1.25B, GAAP loss per share ($0.96)-($1.20), non-GAAP diluted EPS $0.00-$0.23.
- New long-term profitability targets: FY2024 non-GAAP net income 25% of revenue, EBITDA margin 20%; FY2025 30% and 25%.
- Plans to separate oncology business in H2 2023; arbitration with Janssen ongoing, interim award in company's favor.

## SEC filing metadata
- accession: 0001564590-23-001975
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2023-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/0001564590-23-001975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/alks-8k_20230216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-001975
- JSON: https://secwatch.observer/filing/0001564590-23-001975.json
- Plain text: https://secwatch.observer/filing/0001564590-23-001975.txt

## Key facts
- Earnings Releases
  Alkermes plc. reported the quarter ended December 31, 2022 results: revenue $304.7 million, net income $28.3 million, EPS $0.17.
  - Period: the quarter ended December 31, 2022
  - Revenue: $304.7 million
  - Net income: $28.3 million
  - EPS: $0.17
  - Result: reported results
  source text: • Total revenues for the quarter were $304.7 million, compared to $324.5 million for the same period in the prior year. • Net sales of proprietary products for the quarter were $216.1 million, compared to $178.9 million for the same period in the prior year. o Net sales of VIVITROL were $102.0 million, compared to $92.0 million for the same period in the prior year, representing an increase of approximately 11%. o Net sales of ARISTADA 1 were $79.2 million, compared to $78.7 million for the same period in the prior year, representing an increase of approximately 1%. o Net sales of LYBALVI were $34.9 million, compared to $8.2 million for the same period in the prior year, following commercial launch in October 2021. • Total operating expenses for the quarter were $325.3 million, compared to $322.1 million for the same period in the prior year. • Net loss according to generally accepted accounting principles in the U.S. (GAAP) was $28.3 million for the quarter, or a basic and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/0001564590-23-001975-index.htm
- Earnings Releases
  Alkermes plc. updated its the year ending December 31, 2023 guidance (initiated).
  - Period: the year ending December 31, 2023
  - Guidance: initiated
  - Result: guidance update
  source text: On February 16, 2023, Alkermes plc (the “Company”) announced financial results for the three months and year ended December 31, 2022 and financial expectations for the year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/0001564590-23-001975-index.htm
- Earnings Releases
  Alkermes plc. reported the year ended December 31, 2022 results: revenue $1.11 billion, net income $158.3 million, EPS $0.97.
  - Period: the year ended December 31, 2022
  - Revenue: $1.11 billion
  - Net income: $158.3 million
  - EPS: $0.97
  - Result: reported results
  source text: — Revenues of $1.11 Billion in 2022, GAAP Loss per Share of $0.97 and Diluted Non-GAAP Earnings per Share of $0.34 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000156459023001975/0001564590-23-001975-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.